On October 3, 2025, the U.S. Food and Drug Administration (FDA) announced a prioritization pilot program for reviewing abbreviated new drug applications (ANDAs). ANDAs are submissions for generic ...

Abstract: Mobile Crowdsensing (MCS) has become a popular sensing paradigm, where a number of participants use their mobile devices to collectively share and extract information related to a certain ...

This latest FDA program aims to provide speedier reviews for generic drugmakers who produce their products in the U.S. Keeping up its string of pilots in recent months, the FDA on Friday unwrapped a ...

Big pharmaceutical companies are boosting their production capacity of branded medications with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still ...

The U.S. Food and Drug Administration said on Friday that it has launched a new pilot program to speed up the review process for generic drugs that are tested and manufactured entirely in the United ...

A U.S. flag, a U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025. REUTERS/Dado Ruvic/Illustration (Reuters) -The U.S. Food and Drug ...

Against a backdrop of tariff updates and a drug pricing deal from the Trump administration, the FDA charted a pair of moves this week in its push to make drug manufacturing more attractive in the U.S.

The U.S. Food and Drug Administration has launched a new pilot program to speed up the review process for generic drugs that are tested and manufactured entirely in the United States, the regulator ...

The FDA is launching a new pilot prioritization program for the review of abbreviated new drug applications that would provide faster reviews for generic companies that test and manufacture their ...